$47.96
$-2.59 (-5.12%)
End-of-day quote: 04/17/2024
NasdaqGM:JANX
Janux Therapeutics Annual Report
| Year | Year | 2023 | 2022 | 2021 | ||
|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$8.08M | $8.61M | $3.64M | |
| GM % | Gross Margin % |
|
2.60% | 0.00% | 0.00% | |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $-1.32 | $-1.52 | $-1.39 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
-0.00% | -0.00% | -0.00% | |
| Sha. | Shares |
|
46.24m | 41.62m | 41.24m | |
| OCF | Operating Cash Flow |
|
$-50.58M | $-42.92M | $-16.98M | |
| FCF | Free Cash Flow |
|
$-87.00M | $-67.09M | $-18.46M | |
| FCFS | Free Cash Flow Per Share |
|
$-1.19 | $-1.19 | $-0.78 |
